Similar articles

• [Rater-specific interference factors in clinical trials (author's transl)].

  Busch H. Busch H. Pharmakopsychiatr Neuropsychopharmakol. 1977 May;10(3):152-62. doi: 10.1055/s-0028-1094534. Pharmakopsychiatr Neuropsychopharmakol. 1977. PMID: 360240 Clinical Trial. German. No abstract available.
• [Statistical aspects in planning psychotropic drug trials (author's transl)].

  Ferner U. Ferner U. Pharmakopsychiatr Neuropsychopharmakol. 1977 May;10(3):132-9. doi: 10.1055/s-0028-1094530. Pharmakopsychiatr Neuropsychopharmakol. 1977. PMID: 360237 Clinical Trial. German.
• Measurement of compliance.

  Sleator EK. Sleator EK. Psychopharmacol Bull. 1985;21(4):1089-93. Psychopharmacol Bull. 1985. PMID: 4089103 No abstract available.
• Improvement of phase III psychotropic drug trials by intensive phase II work.

  Klein DF. Klein DF. Neuropsychopharmacology. 1991 Jun;4(4):251-8; discussion 259-71. Neuropsychopharmacology. 1991. PMID: 1867735 Review.
• [The clinical evaluation of psychopharmaceuticals in internal and general medicine. Elements for continuing psychopharmacologic and research education of the primary care physician].

  Castillo Pérez P. Castillo Pérez P. An Med Interna. 1988 Sep;5(9):471-81. An Med Interna. 1988. PMID: 2856628 Review. Spanish. No abstract available.